Guardant Health Financials - Benzinga

Guardant Health Inc

GHNASDAQ

Trade with Public

Trade with Public

$185.31

2.721.49%

마지막 업데이트: Oct 29, 4:49 PM

개요 뉴스 실적 전망 이벤트 목표가재무심리 지분 현황 비교 옵션 주식 보고서

© 2026 Benzinga | All Rights Reserved

Guardant Health Financials

Guardant Health (GH) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Guardant Health Raises FY2026 Sales Guidance from $1.300B-$1.320B to $1.340B-$1.360B vs $1.314B Est

Guardant Health (NASDAQ:GH) raises FY2026 sales outlook from $1.300 billion-$1.320 billion to $1.340 billion-$1.360 billion vs $1.314 billion estimate.

Benzinga Newsdesk

PRO
Guardant Health Q2 Adj. EPS $(0.42) Misses $(0.41) Estimate, Sales $334.978M Beat $314.226M Estimate

Guardant Health (NASDAQ:GH) reported quarterly losses of $(0.42) per share which missed the analyst consensus estimate of $(0.41) by 2.44 percent. This is a 4.55 percent increase over losses of $(0.44) per share from

Benzinga Newsdesk

PRO
Guardant Health Raises FY2026 Sales Guidance from $1.250B-$1.280B to $1.300B-$1.320B vs $1.271B Est

2026 GuidanceGuardant Health now expects full year 2026 revenue to be in the range of $1.30 to $1.32 billion, representing growth of 32% to 34% compared to full year 2025. This compares to the prior range of $1.25 to

Benzinga Newsdesk

PRO
Guardant Health Q1 Adj. EPS $(0.45) Beats $(0.76) Estimate, Sales $301.665M Beat $279.198M Estimate

Guardant Health (NASDAQ:GH) reported quarterly losses of $(0.45) per share which beat the analyst consensus estimate of $(0.76) by 40 percent. This is a 8.16 percent increase over losses of $(0.49) per share from the

Benzinga Newsdesk

PRO
Guardant Health Sees FY2026 Sales $1.250B-$1.280B vs $1.238B Est

Guardant Health (NASDAQ:GH) sees FY2026 sales of $1.250 billion-$1.280 billion vs $1.238 billion analyst estimate.

Benzinga Newsdesk

PRO
Guardant Health Q4 Adj. EPS $(0.50) Beats $(0.69) Estimate, Sales $281.266M Beat $271.011M Estimate

Guardant Health (NASDAQ:GH) reported quarterly losses of $(0.50) per share which beat the analyst consensus estimate of $(0.69) by 28.06 percent. This is a 19.35 percent increase over losses of $(0.62) per share from the

Benzinga Newsdesk